Powered by
Wolf Popper LLP Announces Investigation on Behalf of Investors in Stemline Therapeutics, Inc.

Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Stemline Therapeutics, Inc. securities (NASDAQ: STML) during the period January 6, 2017 through February 1, 2017. Such investors are advised to contact Fei-Lu Qian at 877.370.7703 orfqian@wolfpopper.com

Several class action lawsuits have already been filed.  If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2017.  A lead plaintiff is a representative party act

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox